Taiga Biotechnologies Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Taiga Biotechnologies Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013405
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Taiga Biotechnologies Inc (Taiga Biotech) is a biopharmaceutical company that develops protein and cellular therapies. The company develops therapies for diseases including cancers and infectious diseases. Its pipeline products include programs such as stem cell therapy and target specific T-cells. Taiga Biotech’s programs are developed for diseases including HIV and influenza, and hematologic conditions. The company’s technologies for HSCs that provide variety of applications for drug discovery, screening and product development. It conducts research in the clinical areas of red blood cell pharming, vaccine adjuvants cell therapies and bone marrow engraftment enhancer. The company utilizes natural defenses to fight infectious disease and various forms of cancer, including both hematological cancers and solid tumors. Taiga Biotech is headquartered in Aurora, Colorado, the US.

Taiga Biotechnologies Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Taiga Biotech Raises USD6 Million in Venture Financing 10
Taiga Biotech Raises Additional USD8.8 Million in Financing Round 11
Taiga Biotech Raises USD3 Million in Venture Financing 12
Taiga Biotechnologies Inc – Key Competitors 13
Taiga Biotechnologies Inc – Key Employees 14
Taiga Biotechnologies Inc – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Key Facts 2
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Taiga Biotechnologies Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Taiga Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Taiga Biotech Raises USD6 Million in Venture Financing 10
Taiga Biotech Raises Additional USD8.8 Million in Financing Round 11
Taiga Biotech Raises USD3 Million in Venture Financing 12
Taiga Biotechnologies Inc, Key Competitors 13
Taiga Biotechnologies Inc, Key Employees 14

★海外企業調査レポート[Taiga Biotechnologies Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sharp HealthCare:企業の戦略的SWOT分析
    Sharp HealthCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Rosenergoatom Concern:電力:M&Aディール及び事業提携情報
    Summary Rosenergoatom Concern (Rosenergoatom) is a subsidiary of Atomenergoprom, which is electric power generation company, mainly supplying electrical and thermal energy in Russia. The company’s major activities include design, construction, operation and decommissioning of nuclear power plants. T …
  • Nexus AG (NXU):企業の財務・戦略的SWOT分析
    Summary Nexus AG (Nexus) is a healthcare technology company that provides healthcare software solutions. The company provides products such as NEXUS and HIS, a hospital information system; NEXUS and DIS, a special ward and department solutions; and NEXUS and QM, a solution in quality management, amo …
  • M3 Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary M3 Biotechnology Inc (M3 Biotech) is a therapeutics company that concentrates on novel platform of pharmaceuticals that modifies growth-factor systems. The company provides therapies primarily for the treatment of neurodegenerative diseases. It develops small molecule modulators with a conce …
  • Gradalis Inc-製薬・医療分野:企業M&A・提携分析
    Summary Gradalis Inc (Gradalis), formerly Murex Pharmaceuticals, is a biopharmaceutical company which focuses on the development and commercialization of therapies for the treatment of cancer. Its developmental pipeline comprises of candidates for various cancer indications which include ovarian, br …
  • SSM Health Care:企業の戦略的SWOT分析
    SSM Health Care - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • EmCare Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary EmCare Inc (EmCare) is a healthcare service provider that offers emergency department outsourcing services for the hospitals. The center provides emergency medicine, hospital medicine, acute care surgery, anesthesiology and radiology services. It provides recruitment, staffing, management, m …
  • Kirloskar Brothers Ltd (KIRLOSBROS):企業の財務・戦略的SWOT分析
    Kirloskar Brothers Ltd (KIRLOSBROS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • VEON LTD. (VIP):企業の財務・戦略的SWOT分析
    VEON LTD. (VIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • ContourGlobal LP-エネルギー分野:企業M&A・提携分析
    Summary ContourGlobal L.P. (CGLP) is an energy company that owns and operates of power generation assets. It develops, acquires and operates electric power and district heating businesses. The company develops and operates large central power plants in emerging markets to support the growth of the n …
  • PGE Polska Grupa Energetyczna SA (PGE):電力:M&Aディール及び事業提携情報
    Summary PGE Polska Grupa Energetyczna SA (PGE SA) is a state owned energy utility. It generates, trades, transmits, and distributes electricity. The company carries out lignite mining activities, electricity generation from fossil fuels (lignite, hard coal, and natural gas) and renewable energy sour …
  • C&A:企業の戦略・SWOT・財務情報
    C&A - Strategy, SWOT and Corporate Finance Report Summary C&A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Actinogen Medical Ltd (ACW):企業の財務・戦略的SWOT分析
    Summary Actinogen Medical Ltd (Actinogen), formerly Actinogen Ltd is a biotechnology company that develops novel treatments for alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases. The company’s xanamem is a novel drug under development for …
  • Great Eastern Holdings Limited (G07):企業の財務・戦略的SWOT分析
    Great Eastern Holdings Limited (G07) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Bristow Group Inc:企業の戦略・SWOT・財務情報
    Bristow Group Inc - Strategy, SWOT and Corporate Finance Report Summary Bristow Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Snap-on Incorporated:戦略・SWOT・企業財務分析
    Snap-on Incorporated - Strategy, SWOT and Corporate Finance Report Summary Snap-on Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kimal plc:医療機器:M&Aディール及び事業提携情報
    Summary Kimal plc (Kimal) is a medical equipment company that develops, manufactures and markets customised procedure packs and vascular access devices. The company’s products include soft tissue biopsy needles, bone marrow biopsy needles, catheter accessories, catheter lock solution, closure device …
  • Mologic Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company provides products such as bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit, amon …
  • Relmada Therapeutics Inc (RLMDD):企業の財務・戦略的SWOT分析
    Summary Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treat …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆